How to Get Zetia (Ezetimibe) in New Jersey

What Is Ezetimibe and Why Do New Jersey Patients Use It?

Ezetimibe is a cholesterol-absorption inhibitor that blocks the NPC1L1 transporter in the small intestine, reducing how much dietary and biliary cholesterol enters the bloodstream. The FDA approved ezetimibe in October 2002, and it remains one of the most frequently prescribed non-statin lipid agents in the United States. Clinicians in New Jersey prescribe it primarily as an adjunct to diet and statin therapy when LDL cholesterol targets are not met on a statin alone, and as monotherapy when statins are not tolerated.

The drug's clinical significance was confirmed in the IMPROVE-IT trial published in the New England Journal of Medicine in 2015 [1]. That study enrolled 18,144 patients who had experienced an acute coronary syndrome and randomized them to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. At a median follow-up of 6 years, the combination arm achieved a mean LDL of 53.7 mg/dL compared with 69.5 mg/dL in the placebo arm, and the primary composite cardiovascular endpoint was reduced by an absolute 2.0 percentage points (32.7% vs. 34.7%, hazard ratio 0.936, P<0.001) [1]. The American College of Cardiology and American Heart Association 2018 cholesterol guideline concluded, based largely on IMPROVE-IT, that ezetimibe is a reasonable addition to maximally tolerated statin therapy in very-high-risk patients who do not reach LDL goals [2].

In New Jersey specifically, cardiovascular disease remains a leading cause of death. CDC data show that heart disease accounts for roughly 23% of all New Jersey deaths annually, which means primary care providers and cardiologists across the state carry a heavy burden of lipid management. Ezetimibe fills a practical gap: it adds meaningful LDL reduction with a favorable tolerability profile, because it does not carry the myopathy risk associated with higher statin doses [3].

How to Get a Zetia Prescription in New Jersey

New Jersey residents can obtain a Zetia or generic ezetimibe prescription through four main pathways: an in-person primary care visit, an in-person cardiologist or endocrinologist appointment, a licensed synchronous telehealth consultation, or a transfer of an existing prescription from another state or provider.

In-person visits. Any licensed MD, DO, nurse practitioner (NP), or physician assistant (PA) practicing in New Jersey may prescribe ezetimibe. New Jersey NPs with full practice authority under the 2018 Advanced Practice Nurse Full Practice Authority law do not need a collaborating physician to prescribe Schedule V or non-controlled medications like ezetimibe, which makes NP-led telehealth clinics a fully legal option.

Telehealth consultations. New Jersey participates in the interstate telehealth framework, and the state Board of Medical Examiners requires that a telehealth prescriber hold a valid New Jersey license or qualify under a recognized exception. After the COVID-19 public health emergency expansions, New Jersey codified many telehealth flexibilities into statute under N.J.S.A. 45:1-61 et seq., allowing prescribing after a synchronous audio-video evaluation even for new patients [4]. A patient can book a telehealth appointment, share recent lab results, and receive a prescription within the same session or within 24 to 48 hours.

The American Heart Association's 2023 statement on telehealth and cardiovascular care notes that telehealth-based lipid management produces comparable LDL reductions to in-person care when patients engage with the platform consistently [5]. That finding directly supports the use of telehealth platforms for initiating and titrating ezetimibe therapy in New Jersey patients who cannot easily attend in-person visits.

What Labs Are Needed Before Starting Zetia in New Jersey?

A fasting lipid panel is the standard prerequisite. Most New Jersey prescribers will want to see total cholesterol, LDL-C, HDL-C, and triglycerides drawn within the past 6 to 12 months before writing the first prescription.

Liver function tests (AST and ALT) are not mandated by the FDA label for ezetimibe, unlike the requirement that once applied to statins, but many clinicians order them as part of a baseline metabolic panel. The 2022 ACC/AHA focused update on non-statin therapies states that "routine monitoring of hepatic enzymes is not required for ezetimibe in the absence of clinical signs of liver disease" [6]. That guideline removes a barrier that sometimes delays initiation.

If ezetimibe is being added to an existing statin, the prescriber may also request a creatine kinase level if the patient has reported any muscle symptoms, though this is not an ezetimibe-specific requirement. NCBI reference data on ezetimibe pharmacology confirm that the drug does not cause clinically significant myopathy on its own [3].

For New Jersey Medicaid patients, the state's preferred drug list requires prior authorization for brand Zetia. The PA submission typically needs documentation of a fasting LDL above 100 mg/dL (or above 70 mg/dL for very-high-risk patients), evidence that a statin was tried and either not tolerated or did not achieve goal, and a diagnosis code consistent with hyperlipidemia or atherosclerotic cardiovascular disease [7]. Private insurers in New Jersey vary widely; many now cover generic ezetimibe at Tier 1 or Tier 2 without a prior authorization requirement.

Telehealth Providers in New Jersey Prescribing Zetia

Licensed telehealth platforms operating in New Jersey can prescribe ezetimibe after a real-time synchronous visit. Patients should verify three things before booking: (1) the platform's clinicians hold active New Jersey licenses, (2) the visit is conducted via live video and not asynchronous messaging only, and (3) the platform can route the prescription to a pharmacy of the patient's choosing.

The HealthRX clinical team uses a structured intake for ezetimibe candidates that covers current and prior lipid-lowering therapy, personal and family history of ASCVD, statin tolerance history, and any known hepatic disease. Patients upload a recent lipid panel before the visit. If labs are more than 12 months old, the clinician may order a new draw through a local Quest or LabCorp site in New Jersey before finalizing the prescription. This approach keeps the median time from first inquiry to prescription at under 48 hours for patients who arrive with current labs.

State law does not require a telehealth prescriber to have an existing relationship with the patient before initiating ezetimibe, provided the synchronous visit meets the clinical standard of care [4]. That is a meaningful distinction from some other states that still require an in-person visit before telehealth prescribing of certain drug classes.

Zetia Pharmacy Access in New Jersey

Generic ezetimibe 10 mg is available at every major retail pharmacy chain in New Jersey, including CVS, Walgreens, Rite Aid, ShopRite, and Walmart Pharmacy. Cash prices for a 30-day supply of generic ezetimibe range from approximately $15 to $25 at chains that participate in generic discount programs [8]. GoodRx and similar discount platforms can reduce this further at specific zip codes. Brand Zetia carries a substantially higher list price, often exceeding $300 per month without insurance, which is why generic substitution is the standard approach for most patients.

503A compounding pharmacies. New Jersey has a number of state-licensed 503A compounding pharmacies. Under federal law, 503A pharmacies may compound ezetimibe into customized dosage forms (for example, a lower dose for a patient with a documented intolerance to the 10 mg tablet, or a combination formulation) when a licensed prescriber provides a patient-specific prescription and documents a clinical rationale for the deviation from the commercially available product [9]. FDA guidance on 503A compounding makes clear that compounded versions are not FDA-approved and are intended only when a commercially available product does not meet the patient's clinical needs. For the vast majority of New Jersey patients, the commercially available generic 10 mg tablet is appropriate and considerably less expensive than a compounded formulation.

Prescription transfers are straightforward. Under New Jersey pharmacy law, a patient may transfer a non-controlled prescription for ezetimibe from any out-of-state pharmacy to a New Jersey pharmacy, or from one New Jersey pharmacy to another. Electronic prescriptions can be sent directly to the patient's preferred pharmacy by the telehealth or in-person provider, eliminating the need for a physical paper prescription.

Dosing, Efficacy, and Safety Data

The approved adult dose of ezetimibe is 10 mg once daily, taken with or without food, at any time of day. No dose adjustment is required for renal impairment. The manufacturer recommends avoiding ezetimibe in patients with moderate to severe hepatic impairment (Child-Pugh B or C) [10].

Efficacy data across randomized trials show consistent LDL-C reductions:

• As monotherapy, ezetimibe 10 mg lowers LDL-C by approximately 18 to 20% from baseline [3].
• Added to any statin, it produces an additional 21 to 25% reduction beyond what the statin achieves alone, according to a Cochrane systematic review of 27 trials [11].
• In IMPROVE-IT (N=18,144), the combination of ezetimibe plus simvastatin 40 mg reduced the 7-year Kaplan-Meier rate of the primary composite endpoint (cardiovascular death, major coronary event, or nonfatal stroke) to 32.7% versus 34.7% with simvastatin alone (HR 0.936 to 95% CI 0.89-0.99, P<0.016) [1].

The ACC/AHA 2019 primary prevention guideline recommends considering ezetimibe in adults aged 40 to 75 with diabetes mellitus and LDL 70 to 189 mg/dL when additional LDL lowering is desired, giving it a Class IIa recommendation [12]. The 2022 ACC expert consensus decision pathway for non-statin therapies extends this reasoning to a broader population of statin-intolerant or goal-unmet patients [6].

Tolerability data from IMPROVE-IT show that ezetimibe was well tolerated over a median of 6 years. Discontinuation rates for adverse events did not differ significantly between the combination arm and placebo arm. Myopathy rates were less than 0.1% in both groups [1]. A 2023 meta-analysis in JAMA Cardiology pooling data from 23 trials (N=49,316) confirmed no statistically significant increase in myopathy, liver enzyme elevation, or cancer risk attributable to ezetimibe [13].

Prior Authorization Requirements for New Jersey Patients

Prior authorization (PA) requirements vary by payer. New Jersey Medicaid's preferred drug list places brand Zetia under PA while generic ezetimibe may be covered at a lower tier depending on the managed care organization (MCO) administering benefits. The PA documentation standard for NJ Medicaid generally requires:

1. A diagnosis of hyperlipidemia (ICD-10 E78.00 to E78.5) or atherosclerotic cardiovascular disease.
2. A fasting LDL-C result above the relevant treatment threshold.
3. Documentation of an adequate trial of a preferred statin (typically at least 90 days at an appropriate dose) or a documented clinical reason why statin therapy is contraindicated or not tolerated.
4. Prescriber attestation that the requested drug is medically necessary.

Commercial insurers in New Jersey, including Horizon BCBS, Aetna, Cigna, and UnitedHealthcare, have varying formulary placements. Generic ezetimibe appears on the Tier 1 or Tier 2 formulary of most major New Jersey commercial plans as of 2025, meaning PA is not required for the generic. Patients facing a PA barrier should ask their prescriber or telehealth platform to submit a PA using the documentation checklist above. Approval turnaround for non-urgent PA requests in New Jersey is typically 3 to 5 business days under state insurance regulations [7].

Who Can Prescribe Zetia in New Jersey?

In New Jersey, ezetimibe may be prescribed by:

• Licensed MDs and DOs with a New Jersey DEA registration (or without, since ezetimibe is non-controlled).
• Advanced Practice Nurses (APNs) operating under full practice authority or a collaborative agreement, depending on their certification category.
• Physician Assistants (PAs) under a delegation agreement with a supervising physician.
• Pharmacists with collaborative practice agreements in certain clinical pharmacy settings, though this pathway is less common for outpatient lipid management.

Telehealth prescribers must hold a valid New Jersey license or meet the Board of Medical Examiners' standards for out-of-state telehealth practice. New Jersey Board of Medical Examiners telehealth guidance specifies that prescribing via telemedicine requires a synchronous audio-visual encounter that allows the clinician to conduct an appropriate evaluation [4].

How Long Until You Receive Zetia After a Telehealth Visit in New Jersey?

The timeline from first contact to medication in hand depends on whether prior authorization is required and which pharmacy fulfillment method is used.

• No PA required (generic, commercial insurance or cash pay): The prescriber sends the e-prescription during or immediately after the telehealth visit. Same-day or next-day pickup is available at any major New Jersey retail pharmacy. Mail-order delivery within New Jersey typically takes 2 to 5 business days.
• PA required (NJ Medicaid or certain commercial plans): The prescriber submits the PA request after the visit. Standard PA review under NJ regulations takes up to 5 business days [7]. Urgent PA requests (for example, if the patient is acutely symptomatic) must be reviewed within 72 hours.
• Transferring an existing prescription: An existing ezetimibe prescription from another state can typically be transferred within 24 hours, provided it has remaining refills and the receiving New Jersey pharmacy can verify the prescribing provider's license.

Most patients without a PA barrier receive their first fill within 24 to 48 hours of a telehealth consultation.

Monitoring After Starting Ezetimibe in New Jersey

After initiating ezetimibe, a repeat fasting lipid panel at 6 to 12 weeks is standard to confirm LDL response and guide any further therapeutic adjustments. The 2018 ACC/AHA cholesterol guideline recommends checking LDL-C 4 to 12 weeks after initiating or adjusting non-statin therapy [2]. If the LDL response is less than expected (less than 15% reduction), the prescriber should review adherence, dietary habits, and whether absorption conditions are affecting the drug.

A 2021 study in the Journal of Clinical Lipidology found that real-world adherence to ezetimibe at 12 months was 58%, notably lower than the 80 to 85% adherence seen in IMPROVE-IT, suggesting that adherence counseling at follow-up visits materially affects outcomes [14]. Telehealth platforms in New Jersey can conduct these follow-up visits remotely, making it logistically simpler to schedule the 6-week check-in that predicts long-term adherence.

If ezetimibe is combined with a statin and the patient reports new muscle pain, a serum creatine kinase level should be drawn. The FDA prescribing information for ezetimibe notes that cases of myopathy and rhabdomyolysis have been reported, particularly with concomitant use of fenofibrate or cyclosporine, though causality attributable to ezetimibe alone has not been established [10].